肿瘤浸润T淋巴细胞识别甲状腺特异性蛋白及新抗原在滤泡细胞来源甲状腺癌中的研究
该研究探讨了滤泡细胞来源甲状腺癌中肿瘤浸润T细胞的抗肿瘤反应。研究者从原发甲状腺肿瘤和肿瘤累及淋巴结中扩增TIL,通过靶向测序和RNA-seq鉴定新抗原及组织/肿瘤相关抗原,并检测T细胞对甲状腺过氧化物酶、甲状腺球蛋白及BRAFV600E等抗原的反应。结果显示T细胞对甲状腺特异性蛋白和突变相关新抗原存在反应性,支持T细胞靶向免疫治疗探索。
要点
- 甲状腺癌中T细胞浸润常见,但突变负荷低,抗原潜力未知
- TIL对甲状腺过氧化物酶和甲状腺球蛋白反应率分别为84.6%和69.2%
- BRAFV600E特异性T细胞反应见于80%的BRAFV600E阳性患者
核心结论
- 研究证实甲状腺癌患者存在肿瘤抗原特异性T细胞,鼓励进一步探索T细胞靶向免疫治疗用于进展性难治性甲状腺癌。
研究设计与样本
- 从原发甲状腺肿瘤和肿瘤累及淋巴结扩增肿瘤浸润淋巴细胞(TIL和TILN),通过靶向测序和RNA-seq鉴定新抗原及组织/肿瘤相关抗原,并进行HLA分型和T细胞受体β测序,体外通过干扰素γ ELISA和流式细胞术检测T细胞反应性。
主要发现
- 所有甲状腺肿瘤均可见肿瘤浸润T细胞,且可在体外扩增。
- 在6/8例患者中,原发肿瘤和配对TILN存在共享克隆,占测序克隆的1%至10%。
- 对甲状腺过氧化物酶和甲状腺球蛋白的T细胞反应率分别为84.6%(11/13)和69.2%(9/13)。
- 在5例BRAFV600E阳性患者中,4例(80%)检测到BRAFV600E特异性T细胞反应。
- 在TPR-NTRK1阳性和CCDC6-RET阳性甲状腺癌患者中检测到针对基因融合来源新抗原的T细胞。
临床怎么用
- 甲状腺癌中存在肿瘤抗原特异性T细胞,提示T细胞靶向免疫疗法可能对进展性难治性甲状腺癌有探索价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thyroid cancers are among the growing list of cancer types that are resistant to immune-checkpoint inhibitor monotherapy. Although T-cell infiltration is common in follicular cell-derived thyroid cancers, tumor mutation burden is low. The antigenic potential of thyroid cancers is unknown. METHODS: To investigate the anti-tumor T-cell response in thyroid cancer, we expanded tumor-infiltrating lymphocytes (TIL) from primary thyroid tumors and tumor-involved lymph nodes (TILN). Putative neoantigens and both tissue-associated and tumor-associated antigens were identified by targeted sequencing and RNA-seq. HLA typing was performed for all patients, and neoantigen binding potential was predicted for each patient using NetMHCpan 4.1 and NetMHCIIpan 4.0 algorithms. In parallel, T-cell receptor β sequencing was performed to detect T-cell clonal expansions in patient-matched primary tumors and TILN. TIL reactivity to tumor-associated antigens and neoantigens was determined in vitro by interferon γ ELISA and flow cytometry. RESULTS: Tumor-infiltrating T cells were evident in all thyroid tumors and readily expanded ex vivo. Shared clones were present in primary thyroid tumors and matched TILN in all patients tested, constituting 1% to 10% of the sequenced clones in 6/8 patients. T-cell reactivity to thyroid tissue-specific proteins, thyroid peroxidase and thyroglobulin, was observed in 84.6% (11/13) and 69.2% (9/13) patients, respectively. A BrafV600E-specific T-cell response was evident in 80% (4/5) BrafV600E+ patients. T cells reactive to gene fusion-derived neoantigens were detected in patients with TPR-NTRK1+ and CCDC6-RET+ thyroid cancer. CONCLUSION: Our studies confirm the presence of tumor antigen-specific T cells in patients with thyroid cancer and encourage further exploration of T cell-targeted immunotherapies for patients with progressive, treatment refractory thyroid cancer.
引用
- Garza B, Calhoun J, Norman PJ, et al. Tumor-infiltrating T Lymphocytes Recognize Thyroid-specific Proteins and Neo-antigens in Follicular Cell-derived Thyroid Cancers. J Clin Endocrinol Metab. 2026. PMID: 41275380. doi:10.1210/clinem/dgaf639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。